Primary membranous nephropathy in two siblings with one combined with anti-glomerular basement membrane disease: a case report.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
22 06 2023
Historique:
received: 30 12 2021
accepted: 20 03 2023
medline: 26 6 2023
pubmed: 23 6 2023
entrez: 22 6 2023
Statut: epublish

Résumé

The phospholipase A2 receptor (PLA2R) associated with membranous nephropathy (MN) is an organ-specific autoimmune disease associated with PLA2R and human leukocyte antigen (HLA) genes. Familial PLA2R-related MN is rarely reported. The combination of anti-GBM disease and MN has been well documented, though the mechanism behind it remains unclear. We describe two siblings diagnosed with pathology-confirmed PLA2R-related MN 1 year apart. And one of the two siblings developed an anti-GBM disease. The high-resolution HLA typing showed identical alleles in both siblings, specifically heterozygotes of DRB1*15:01/*03:01. We describe a familial case of PLA2R-related MN supporting the role of genetic factors that HLA-DRB1*15:01 and DRB1*03:01 predispose patients in the development of PLA2R-related MN in the Han Chinese population. The combination of MN and anti-GBM disease may also partially be associated with the same susceptible HLA allele DRB1*15:01.

Sections du résumé

BACKGROUND
The phospholipase A2 receptor (PLA2R) associated with membranous nephropathy (MN) is an organ-specific autoimmune disease associated with PLA2R and human leukocyte antigen (HLA) genes. Familial PLA2R-related MN is rarely reported. The combination of anti-GBM disease and MN has been well documented, though the mechanism behind it remains unclear.
CASE PRESENTATION
We describe two siblings diagnosed with pathology-confirmed PLA2R-related MN 1 year apart. And one of the two siblings developed an anti-GBM disease. The high-resolution HLA typing showed identical alleles in both siblings, specifically heterozygotes of DRB1*15:01/*03:01.
CONCLUSION
We describe a familial case of PLA2R-related MN supporting the role of genetic factors that HLA-DRB1*15:01 and DRB1*03:01 predispose patients in the development of PLA2R-related MN in the Han Chinese population. The combination of MN and anti-GBM disease may also partially be associated with the same susceptible HLA allele DRB1*15:01.

Identifiants

pubmed: 37349681
doi: 10.1186/s12882-023-03132-2
pii: 10.1186/s12882-023-03132-2
pmc: PMC10286333
doi:

Substances chimiques

Autoantibodies 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

183

Informations de copyright

© 2023. The Author(s).

Références

Int J Pediatr Nephrol. 1984 Dec;5(4):193-6
pubmed: 6597809
J Am Soc Nephrol. 2017 May;28(5):1651-1664
pubmed: 27852637
Kidney Int. 2018 Nov;94(5):974-982
pubmed: 30173899
Nephrol Dial Transplant. 1995;10(1):108-10
pubmed: 7724003
J Am Soc Nephrol. 2019 Jun;30(6):1123-1136
pubmed: 31061139
J Am Soc Nephrol. 2017 May;28(5):1642-1650
pubmed: 28028136
J Nephrol. 2018 Apr;31(2):271-278
pubmed: 29081027
Nephron. 1991;58(3):320-4
pubmed: 1896097
Am J Kidney Dis. 2021 Aug;78(2):219-225.e1
pubmed: 33421452
Kidney Int. 2014 Apr;85(4):945-52
pubmed: 24048374
Kidney Int. 2020 Jan;97(1):163-174
pubmed: 31901340
N Engl J Med. 2014 Dec 11;371(24):2277-2287
pubmed: 25394321
N Engl J Med. 2009 Jul 2;361(1):11-21
pubmed: 19571279
Kidney Int Rep. 2019 Aug 13;4(11):1577-1584
pubmed: 31890999
Immunology. 2017 Aug;151(4):395-404
pubmed: 28342268
Nat Commun. 2020 Mar 30;11(1):1600
pubmed: 32231244
Nephron. 1988;50(1):79-80
pubmed: 3173611
N Engl J Med. 2011 Feb 17;364(7):616-26
pubmed: 21323541
J Nephrol. 2021 Apr;34(2):597-601
pubmed: 32524521

Auteurs

Yan-Jiao Cheng (YJ)

Renal Division, Peking University First Hospital, Beijing, 100034, PR China.
Institute of Nephrology, Peking University, Beijing, 100034, PR China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, 100034, PR China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, 100034, PR China.

Xiao-Yu Jia (XY)

Renal Division, Peking University First Hospital, Beijing, 100034, PR China. constancej@163.com.
Institute of Nephrology, Peking University, Beijing, 100034, PR China. constancej@163.com.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, 100034, PR China. constancej@163.com.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, 100034, PR China. constancej@163.com.

Hong-Ru Cao (HR)

Renal Division, Affiliated Hospital of Chifeng University, Chifeng, 024005, PR China.

Xiao-Yi Zhao (XY)

Renal Division, Affiliated Hospital of Chifeng University, Chifeng, 024005, PR China. zxy5080@163.com.

Xu-Jie Zhou (XJ)

Renal Division, Peking University First Hospital, Beijing, 100034, PR China.
Institute of Nephrology, Peking University, Beijing, 100034, PR China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, 100034, PR China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, 100034, PR China.

Xiao-Juan Yu (XJ)

Renal Division, Peking University First Hospital, Beijing, 100034, PR China.
Institute of Nephrology, Peking University, Beijing, 100034, PR China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, 100034, PR China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, 100034, PR China.

Rong Xu (R)

Renal Division, Peking University First Hospital, Beijing, 100034, PR China.
Institute of Nephrology, Peking University, Beijing, 100034, PR China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, 100034, PR China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, 100034, PR China.

Fu-de Zhou (FD)

Renal Division, Peking University First Hospital, Beijing, 100034, PR China.
Institute of Nephrology, Peking University, Beijing, 100034, PR China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, 100034, PR China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, 100034, PR China.

Su-Xia Wang (SX)

Renal Division, Peking University First Hospital, Beijing, 100034, PR China.
Institute of Nephrology, Peking University, Beijing, 100034, PR China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, 100034, PR China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, 100034, PR China.

Zhao Cui (Z)

Renal Division, Peking University First Hospital, Beijing, 100034, PR China.
Institute of Nephrology, Peking University, Beijing, 100034, PR China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, 100034, PR China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, 100034, PR China.

Ming-Hui Zhao (MH)

Renal Division, Peking University First Hospital, Beijing, 100034, PR China.
Institute of Nephrology, Peking University, Beijing, 100034, PR China.
Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, 100034, PR China.
Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, 100034, PR China.
Peking-Tsinghua Center for Life Sciences, Beijing, 100871, PR China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH